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Various technologies are commonly used to support type 1 diabetes management 
(continuous subcutaneous insulin infusion therapy; continuous glucose monitoring 
systems; smartphone and tablet applications; and video-conferencing) and may foster 
self-care, communication and engagement with healthcare services. Diabetes Educators 
are key professional supporters of this patient group, and ideally positioned to promote 
and support technology use. The aim of this study was to examine Diabetes Educators’ 
perceived experiences, supports and barriers to use of common diabetes-related 
technologies for people with type 1 diabetes. 
METHODS 
This qualitative ethnographic study recruited across metropolitan, regional and rural areas 
of Australia using purposive sampling of Australian Diabetes Educators Association 
members. Data were collected by semi-structured telephone interviews and analysed 
using thematic analysis. 
RESULTS 
Participants (n=31) overwhelmingly indicated that overall the use of technology in the 
care of patients with type 1 diabetes was burdensome for them. They identified three 
themes involving common diabetes-related technologies: access to technology, available 
support and technological advances. Overall, these themes demonstrated that whilst care 
was usually well-intentioned it was more often fragmented and inconsistent. Most often 
care was provided by a small number of Diabetes Educators who had technology 
expertise. 
CONCLUSIONS 
To realise the potential benefits of these relatively new but common diabetes 




deliver this essential component of care. Further, policy and strategy review is required, 






The incidence of type 1 diabetes (T1D) is rising approximately 3% per annum 
internationally [1]. The substantial impact of T1D on health and disease burden has been 
documented, as has the importance of tight glycaemic control to avoid or defer disease 
complications [2, 3]. The majority of adult diabetes services are oriented towards the 
management of type 2 diabetes, the most common diabetes form [4, 5]; as a consequence, 
people with T1D may find it hard to access disease or age-specific care. 
 
Technology can provide innovative approaches to T1D healthcare [6]. Common 
technologies can be broadly categorised as related to insulin delivery, blood glucose 
monitoring and communication, each category with multiple media. For insulin delivery, 
compared to injections, continuous subcutaneous insulin infusion (CSII; insulin pump) 
therapy has demonstrated improved quality of life, glycaemic control for some, reduced 
mortality and economic benefit [7-14]. With usage increasing, by 2011 in Australia 
approximately 10% of the T1D population were using CSII technology, with half of all 
users aged under 25 years [15]. Many CSII devices are obtained through a government 
subsidy for low income families with children with T1D, introduced in 2008 or, more 
commonly, private health insurance [16]. 
 
Insulin dosage calculation is reliant on blood glucose monitoring. Continuous glucose 
monitoring (CGM) technology overcomes the limitations of intermittent monitoring and 
has been associated with HbA1c reduction without increased hypoglycaemia risk, higher 
treatment satisfaction and improved quality of life [6, 14, 17, 18]. Software packages 
currently available for both CSII therapy and CGM systems enable transfer of data to a 
healthcare professional (HCP) via the internet [19]. However, use is limited by the 





Specialised program applications (‘apps’) downloaded on smart phones and tablets 
support self-care through timely provision of information on blood glucose, diet and 
exercise patterns; and this information can be shared electronically with healthcare 
providers [19, 21, 22]. Another communication modality is video-conferencing (VC), 
which allows simultaneous audio and visual communication between two or more 
locations via the internet [6]. This may involve commercial systems managed by 
healthcare organisations or personal communication software such as SkypeTM. Besides 
clinical care, VC can also be used for continuing education [23]. 
 
Support from a skilled multi-disciplinary team is required to achieve the potential 
benefits offered by common diabetes-related technologies, with Diabetes Educators 
(DEs) being key members of this team. When considering CSII use, for example, they 
may help determine insulin dosage requirements, support achievement of therapy benefits 
and mitigate the challenges and risks [24, 25]; reported to be common with devices, 
associated consumables and the user [25]. With little information how this occurs, this 
study aimed to examine DEs’ perceived experiences, supports and barriers to use of 




Design and data collection 
This was a qualitative study undertaken June-August 2014 using an ethnographic design. 
Data were collected by individual semi-structured telephone interviews, allowing topics 




encourage detailed responses, and enabling participation across wide geographical 
distances [26]. 
 
The interview schedule was developed by research team members, and piloted with two 
Canadian based DEs. Topics included participants’ experience of working with each type 
of technology; the impact of supporting these technologies on workload; perceived 
supports and barriers to their use; and the influence of work environments on uptake and 




A purposive sample was collected from members of the Australian Diabetes Educators 
Association (ADEA); the leading Australian organisation for multidisciplinary HCPs 
who provide diabetes education and care. This sampling technique was chosen to obtain a 
wide cross-section of participants with collective experience with the four technologies. 
Participants were eligible for the study if they had current ADEA membership, current or 
past experience as a DE in Australia and in use of CSII, CGM, apps and/or VC. They 
were required to be able to converse in the English language, have access to a telephone 
and an email address. Recruitment ceased when data saturation had been reached and it 
was deemed there were no new data to gather. 
 
Procedure 
Two hundred and thirteen members who responded to advertisements in the ADEA 
newsletter and completed an anonymous web-based survey (published elsewhere [6]), 
were supplied with study information and invited to participate; interested participants 




professional standing as a DE facilitated development of the trust necessary to share 
private, sensitive or controversial details [27, 28]. It also enabled understanding of 
participants’ frame of reference, and potential exploration of contextual points or ideas 
raised. Personal preconceptions and biases were addressed through maintenance of a 
reflexive journal, peer debriefing and triangulation [29]. Field notes were collected 
during and after each interview, which was audio recorded after an introduction where 
confidentiality principles were reinforced. Approval was obtained from the University of 
Technology Sydney Human Research Ethics Committee. 
 
Data analyses 
Audio data and field notes were transcribed verbatim into Microsoft Office Word 
2010TM, de-identified and imported into NVivo 10TM software. Data were analysed using 
Gibb’s [30] framework, which entailed transcription and familiarisation, code building, 
theme development, and data consolidation and interpretation. Transcripts were available 
to participants for comment. They were read by all authors; the first author initiated 





Interviews were conducted with DEs (n = 31) who worked across metropolitan, regional 
and rural areas (Table 1). Most were female (90.3%) and Registered Nurses (96.8%), 
although working at differing levels of expertise and responsibility. Interviews lasted 





Participants overwhelmingly perceived technology use as personally burdensome, when 
considering the increased demands that this placed on themselves and the need to 
occasionally use personal resources. Many wanted help, particularly to support patients 
with CSII. Three themes detailed perceived supports and barriers to involvement with 
common diabetes-related technologies in the care of patients with T1D: access to 
technology; availability of support; and technological advances. 
 
Access to technology 
Access to technology was often difficult, both for patients and DEs. Patient access to 
CSII was limited by device costs, seen as prohibitive for many. The current Australian 
government subsidy, whilst considered beneficial, was not available to young adults, 
many of whom were unable to self-fund these devices. The absence of government CSII 
device support after age 18 years resulted in some patients being unable to replace and so 
continuing to use old and defective equipment. Participants felt obliged to support 
patients with minimally functioning devices, even though it was not seen as in their best 
interests: 
 
“I had a chap the other week that didn’t even have a face on his pump 
[CSII]….he’s still using it six months after I asked him not to.” (DE23:Metro) 
 
Another barrier to access was the lack of systematic processes for determining the 
balance of benefit and risk from device use for individual patients. Often DEs were 
expected to take responsibility to gate keep this technology without formal organisational 





“It’s generally up to the DE who will see the patient first. They will deem if they 
think it [CSII] is suitable.” (DE-53:Metro) 
 
Similar access difficulties were described in relation to CGM technology. Participants, 
especially those working in hospitals, expressed frustration with their lack or limited 
access to CGM devices, transmitters and sensors, and that they often did not have 
adequate software and computer access to download CGM or CSII data direct from 
devices. They also perceived the cost of CGM technology as prohibitive to consumers, 
and appreciated when diabetes centres could fund CGM sensors. This occurred where 
DEs judged there was clinical need, a decision seldom underpinned by any formal policy 
or guidance. Where hospitals, and sometimes private DE practitioners, loaned CGM 
devices and/or transmitters to patients, this was seldom covered by a specific 
organisational infection control policy; devices were however routinely cleansed upon 
return. Highlighting co-operation between paediatric and adult diabetes services to 
increase CGM access in a regional setting, one DE stated: 
 
“The paediatric unit actually paid for the device [CGM]….I get the adults to pay 
for their sensors.” (DE-92) 
 
Difficulties with access were also described in relation to apps. Participants expressed 
their frustration that apps were not available across all brands and models of smartphones 
and tablets. They highlighted that many patients lack access to this technology and Wi-Fi 
coverage. However, this was also not provided to many DEs by their employers, and 





Access to VC was mixed. Participants employed within hospitals, particularly in 
metropolitan areas, largely reported access to commercial VC systems, usually shared 
across health disciplines. However, the cost of such systems was prohibitive for smaller 
diabetes services, general practices and private DE practitioners. Instead, many 
participants in regional and rural localities used free personal communication software 
such as SkypeTM. Originally banned, SkypeTM use was now often approved. However, 
network coverage in non-metropolitan areas was often erratic, especially outside of 
school hours, resulting in inconsistent visual and sound quality, and outages. This often 
deterred use. 
 
Availability of support 
Time constraints were a barrier to participants’ involvement with all technologies; CSII 
and CGM, particularly, were perceived to negatively impact workload. Recognising the 
number of interactions required to commence a patient on CSII, one DE stated: 
 
“We’ve got [small number] educators so if a person wants to go on a pump 
[CSII] you’ve got one educator out (i.e. solely preoccupied with that patient) for 
a day and a half.” (DE-22:Metro) 
 
Participants expressed their frustrations at insufficient DE staffing for their patient 
numbers and lack of staff skilled in CSII and CGM, in particular. Considering the 
increasing uptake, they were anxious how they would cope into the future, especially 
within paediatric settings. However they valued the support received from DE colleagues. 
 
Participants also expressed their discomfort working with patients who had commenced 




diabetes service. Many in regional and rural localities were suspicious that funding 
incentives from CSII companies, rather than patient needs, drove decisions to commence 
patients on this method of insulin delivery in metropolitan centres. Their concern was that 
these patients later sought follow-up, and in the event of related ill-health, presented to 
their local diabetes service or hospital, which was often under-staffed and under-skilled 
for this. 
 
“Multiple metropolitan centres….would be happy to take a referral to initiate a 
pump [CSII], but that’s the end of the service provided.” (DE-11:Rural) 
 
Limitations to Australian government Medicare rebates meant that many private DE 
practitioners were unpaid for much of the work they undertook. This acted as a barrier 
towards further involvement with CSII, CGM and VC. One DE stated: 
 
“The patients have to pay to see me or they had EPCs [enhanced primary care 
plans – government funding] that they could put through. I put in a lot of time 
and effort that I was never reimbursed for.” (DE-9:Regional) 
 
Managers and physicians could be supportive towards technology use, for example, by 
advocating for and securing related funding. However they could also act as barriers to 
involvement. Medical staff who had qualified from medical school years earlier were 
viewed particularly negatively when considering their views towards use of apps and 
CSII. Especially in community and general practice settings, little hands-on support was 
available to DEs for CSII and CGM use. General practitioners were perceived to have 




to DEs. Participants also highlighted endocrinologists’ under-use and occasional 
unwillingness to use VC. 
 
There was concern at lack of funding for on-call DE staffed services to provide advice in 
emergencies for CSII and CGM users outside of office hours: device failure, acute 
diabetes-related complications and sick-day management, for example. In rare instances 
where on-call services were available, these were staffed by physicians with limited 
knowledge of these technologies. As a consequence, many participants provided selected 
patients with their personal contact details; criteria for such decisions were unclear: 
 
“There’s no point in them going to hospital because….They are not upskilled 
with using the pump [CSII]….If we can avoid an admission, I prefer to give them 
my personal mobile number.” (DE-12:Regional) 
 
Support was available from the manufacturers of CSII and CGM technologies through 
telephone help-lines for patients and HCPs. These were deemed very helpful by DEs, 
though concerns were raised at calls being diverted to agents in other countries and the 
sometimes “textbook” advice provided. Companies also loaned devices and transmitters, 
and provided consumables, trial sensors and ongoing education. However, for VC, 
participants identified very limited and sometimes complete absence of organisational 
training. They also had concerns about the support and facilities at connecting sites. 
Information technology departments were seen as both supportive and barriers to 






Participants had difficulty keeping up to date with advances in design and programming 
of CSII and CGM devices. They relied almost exclusively on information from 
companies. They struggled to maintain the regular software updates required for full 
functioning, in the face of barriers to downloading, organisational hurdles and computer 
firewalls. 
 
Similar difficulties were reported in keeping up to date with apps, especially because of 
their increasing numbers and the workload burden this represented. Participants primarily 
relied on obtaining information at conferences, but also from DE colleagues, companies, 
patients and professional magazines: 
 
 “Everybody’s so busy rowing the boat that they don’t have time. Our flow 
through is not dropping, it’s getting bigger…. and you get less funding, less 
resources.” (DE-27:Metro) 
 
DEs were unable to make best use of data collected through apps and CGM systems. 
They highlighted concerns regarding the formats in which data were provided, based on 
programming deficiencies and the difficulties experienced interpreting such data. Patients 
were also not always good at providing complete information, with records omitting 
important details such as carbohydrate consumption and exercise undertaken. 
 
“They send me information and you just can’t work out what time it was and all 








Our research provides important insights into DEs’ experiences and perceptions of what 
supports and limits the use of common diabetes-related technologies for patients with 
T1D in Australia. Overall, themes demonstrated that whilst care was usually well-
intentioned it was more often fragmented and inconsistent, and not often enough 
delivered with appropriate technology expertise. Change is clearly needed at multiple 
levels of the Australian healthcare system to facilitate DEs’ technology adoption and 
realisation of the potential of these technologies for improved patient outcomes and 
support. 
 
Firstly, findings reveal that DEs need support to attain and retain the skills required to 
deliver these essential components of care. They mesh with findings from the anonymous 
web-based survey from which the sample derived (published elsewhere [6]), which 
highlighted the need for DEs’ ongoing education to promote technology adoption. 
Though the support need around skills may lessen in the future with the generational ages 
of participants predominantly not indicative of ‘digital natives’ [31], in the meantime 
organisational and managerial support in the form of funding and time allowance (both 
study time to gain the skills and time to use them) would assist, as would rotating 
placements across and between paediatric and adult diabetes care settings. Besides 
increasing DEs’ technology exposure, this may better align the norms of practice in 
different settings for greater consistency of patient experience [6]. Mentorship schemes 
should also be established and promoted; external stakeholders such as the ADEA may 
be able to assist [32]. They could also assist by providing periodic detailed summaries of 
evolving CSII and CGM systems and apps, in view of participants’ difficulties keeping 





Support for DEs in providing technology-based care delivery could involve service 
reconfiguration. In some areas this may necessitate reallocation of staffing and resources 
and improved infrastructure. Cross-coverage from areas where technology-based 
expertise exists would also assist, enabled by maximisation of VC use. Besides 
facilitating DE peer support and professional development, VC could also be the medium 
to provide support directly for patients, to make communication more flexible and care 
more efficient [23]. Information technology departments have an important role in this, 
and access to such support should be maximised. 
 
A review of policy and strategy is also required of the allocation of devices to patients, of 
the role of patients in choosing insulin delivery and glucose monitoring systems, and the 
processes for ensuring support from healthcare providers. The absence of consistent 
policies relating to CSII and CGM compounded the confusion reported both within and 
between services. Recent Australian CSII clinical guidelines feature assessment of patient 
suitability for CSII use [33, 34], and state guidelines make recommendations for in-
hospital CSII care [35]. These should be promoted and adopted, and local policies 
formulated from these documents to translate guidelines into practice. 
 
Australian government policy for access to common diabetes-related technologies, 
especially CSII, requires review. The current government CSII device subsidy ceases 
once a child reaches age 18 years [16]. However, considering the importance of optimal 
glycaemic control to minimise diabetes complications, and hence their associated costs 
[7, 36], there is a case to extend the subsidy to enable CSII use to continue safely through 





Review is also required of the Australian government Medicare rebates available to 
private DE practitioners; lack of reimbursement was reported as a barrier to DEs 
involvement with CSII, CGM and VC. Existing rebates do not take full account of the 
time required to commence a patient on CSII, reported as median 18.6 hours and 14.1 
interactions over 11.8 weeks [33]. Rebates only cover five ‘face-to-face’ visits and do not 
fund consultations undertaken via VC although HCPs other than DEs are able to utilise 
this technology [37]. 
 
Study limitations include that recruitment methods targeted only members of ADEA, and 
participants self-selected; findings may not be representative of all DEs [38]. There was 
no quantification of participants’ experience with the technologies; limited exposure may 
have influenced perceptions. Nonetheless, strengths derive from the number of interviews 
undertaken, recruitment across diverse and wide sociological and geographical areas, and 




This research provides important insights into the perceptions of an essential professional 
group in the care of patients with T1D, in relation to what supports and deters use of 
common diabetes-related technologies. Difficult access to technology; limited availability 
of support; and relentless but inaccessible technological advances influenced DEs’ 
involvement. Findings suggest that to maximise technology adoption and support many 
DEs need to attain and retain the skills required to deliver this essential component of 
care. Further, there is a need for review of policy and strategies, followed by 
reconfiguration of services to support care delivery and realise the potential benefits of 

















































































































































Table 1: Interviewee characteristics 
 n Male RN APD Age 
(mean (SD))* 
Rural 6 2 6 0 48 (10.6) 
Regional 9 0 9 0 53 (4.7) 
Metro 16 1 15 1 49.6 (5) 
Total 31 3 30 1 50 (6.4) 
n=Number.    RN=Registered Nurse.    APD=Accredited Practising Dietician. 
*=in years.    Metro=Metropolitan 
